The peptic ulcer is an open sore that develops on the upper portion of the small intestine and inside the lining of the stomach. This type of ulcer is mainly two types including gastric ulcers and duodenal ulcers. Some of the key symptom of peptic ulcer includes vomiting, bloating, and stomach pain. A peptic ulcer is caused by excess use of aspirins and Helicobacter pylori infection. These ulcers require to be treated as if untreated; they can cause different implications for instance perforation and bleeding in the stomach lining.
As per analysis, “COVID-19 Impact on Global Peptic Ulcer Drugs Market by Disease Indication (Gastric Ulcers, Duodenal Ulcers, and Esophageal Ulcers); By Application (Hospital Pharmacies, Drug Stores, Retail Stores and Online Sales) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030” the key companies operating in the global peptic ulcer drugs market include Zuventus Healthcare, Takeda Pharmaceutical Co. Ltd., PharmaKing, Johnson and Johnson, Ferring Pharmaceuticals, Otsuka Holdings, PharmaKing, Eumedica, Taiho Pharmaceutical, Daiichi Sankyo and among others.
By disease indication, the market is categorized as duodenal ulcers, gastric ulcers and esophageal ulcers. Gastric ulcers segment dominates the global market owing to the high prevalence of diseases. In addition, by application, market is categorized as retail stores, hospital pharmacies, online sales, and drug stores. Hospital pharmacies segment is predicted to exhibit a considerable growth rate due to increase in hospital numbers and wide variety of services delivered at single site during the forecast period.
The market is driven by increase in number of generic producers of peptic ulcer drugs, followed by surge in patient pool suffering from ulcers, improvement in diagnostic technique, rise in number of manufacturers producing the drug, growth in population, increase in Research & Development (R&D) through government policies. However, fluctuation in the cost of the drugs and side effects associated with the use of this drug may impact the market.
The most unprecedented operational & economic challenges have emerged due to the ongoing COVID-19 pandemic, which is an acute respiratory distress syndrome caused by the novel Corona Virus. In addition, a considerable period of time is mandatory for the development & commercialization of effectual treatment options for this novel pathogen of COVID-19. The peptic ulcer drugs market is likely to recover to pre-pandemic market demand caused by the availability of COVID-19 vaccinations. Moreover, local governments are prioritizing healthcare resources to tackle Corona Virus challenges, which are also projected to slow down the progress of peptic ulcer drugs market in the short term.
By regional analysis, the North-America holds major share in global market owing to increase in incidence of peptic ulcers and rise in use of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin across the region. The Europe and Asia-Pacific regions are estimated to exhibit higher CAGR due to simple availability of effective treatment options for peptic ulcers coupled with rise in healthcare expenditure over the forecast period. It is predicted that future of the global market will be bright as a result of increase in prevalence of stress-induced ulcers caused by changing lifestyle & diet, progressive geriatric population and increased smoking rates during the forecast period.
For More Information on the Research Report, refer to the below links: –
Ankur Gupta, Head Marketing & Communications